

# REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:

File Information Unit  
Crystal Plaza Three, Room 1D01  
2021 South Clark Place  
Arlington, VA  
Telephone: (703) 308-2733

RECEIVED

AUG 21 2003

File Information Unit

In re Application of

Application Number

09/843694

Filed

04-30-01

Paper No.

#19

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. \_\_\_\_\_, page, \_\_\_\_\_ line \_\_\_\_\_.

United States Patent Number 2003/0022932, column \_\_\_\_\_, line, \_\_\_\_\_ or

WIPO Pub. No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_.

## Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:

For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
  - the file contents;
  - the pending application as originally filed; or
  - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
  - the pending application as originally filed.

Shorib Ghayour

Signature

Shorib Ghayour

Typed or printed name

Registration Number, if applicable

Telephone Number

08-21-03

Date

FOR PTO USE ONLY

RECEIVED

Approved by

(initials)

AUG 21 2003

Unit:

File Information Unit



US 20030022937A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2003/0022937 A1****Veech**(43) **Pub. Date: Jan. 30, 2003**(54) **THERAPEUTIC COMPOSITIONS****Publication Classification**(75) **Inventor: Richard L. Veech, Rockville, MD (US)**(51) **Int. Cl.<sup>7</sup> ..... A61K 31/225; A61K 31/335;  
A61K 31/19**

**Correspondence Address:**  
**NIXON & VANDERHYE P.C.**  
**8th Floor**  
**1100 North Glebe Road**  
**Arlington, VA 22201 (US)**

(52) **U.S. Cl. .... 514/557; 514/547**(73) **Assignee: BTG International Limited**(57) **ABSTRACT**(21) **Appl. No.: 10/153,873**(22) **Filed: May 24, 2002****Related U.S. Application Data**

(63) Continuation of application No. 09/843,694, filed on Apr. 30, 2001, now abandoned, which is a continuation of application No. 09/397,100, filed on Sep. 16, 1999, now Pat. No. 6,323,237, which is a continuation of application No. PCT/US98/05072, filed on Mar. 17, 1998.

(60) Provisional application No. 60/040,858, filed on Mar. 17, 1997.

Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.